Bhaskar Manju, Jagtap A G
Department of Pharmacology, Bombay College of Pharmacy, Kalina, Santacruz (E), Mumbai, Maharashtra, India.
Int J Ayurveda Res. 2011 Jan;2(1):2-7. doi: 10.4103/0974-7788.83173.
Earlier studies have demonstrated that Bacopa monniera (BM), a plant described in Ayurveda for many CNS actions was found to exhibit antidepressant (methanolic extract at 20mg/kg and 40mg/kg p.o.) as well as antinociceptive activity (aqueous extract (AE) at 80 mg/kg, 120 mg/kg and 160 mg/kg p.o.). The present study sought to explore the possible mechanisms of antinociceptive effects of aqueous extract of Bacopa monniera (AEBM) at 80 mg/kg, 120 mg/kg and 160 mg/kg given orally.
AEBM was given singly as well as with selective α2 receptor blocker Yohimbine, selective β1 receptor blocker Atenolol, serotonin receptor antagonist Cyproheptadine and a non-selective opioid receptor antagonist naloxone in experimental groups of mice and rats under strict protocols and conditions.
We observed that the antinociceptive effects of AEBM in the acetic acid writhing test was prevented by prior treatment with the selective Yohimbine (1 mg/kg, i.p; 14.50 ± 2.26 and 37.17 ± 2.14 writhes in the AEBM-treated and yohimbine pre-treated AEBM groups, respectively) and selective β1 Atenolol receptor blocker (1 mg/kg, i.p; 14.50 ± 2.26 and 31.00 ± 5.44 writhes in the AEBM-treated and yohimbine pre-treated AEBM groups, respectively). In the formalin test, the reduction in licking time with AEBM was found to be reversed by prior treatment with serotonin receptor antagonist Cyproheptadine (1 mg/kg, i.p; 47.33 ± 2.25s and 113.50 ± 3.83s (during phase I i.e. 0-5 min) and 26.67 ± 3.83s and 88.17 ± 7.27s (during phase II i.e. 20-30 min) in the AEBM-treated and Cyproheptadine pre-treated AEBM groups, respectively). The % increase in tail flick latency with AEBM was prevented by prior treatment with the non-selective opioid receptor antagonist naloxone (2mg/kg, i.p; 282.35 and 107.35 in the AEBM-treated and naloxone-treated groups, respectively).
Our results indicate, that the endogenous adrenergic, serotonergic and opioidergic systems are involved in the analgesic mechanism of action of the aqueous extract of Bacopa monniera.
早期研究表明,印度草药中记载的一种对许多中枢神经系统有作用的植物——假马齿苋(BM),其甲醇提取物(20mg/kg和40mg/kg口服)具有抗抑郁活性,而其水提取物(AE,80mg/kg、120mg/kg和160mg/kg口服)具有抗伤害感受活性。本研究旨在探讨假马齿苋水提取物(AEBM)80mg/kg、120mg/kg和160mg/kg口服给药时抗伤害感受作用的可能机制。
在严格的方案和条件下,将AEBM单独以及与选择性α2受体阻滞剂育亨宾、选择性β1受体阻滞剂阿替洛尔、5-羟色胺受体拮抗剂赛庚啶和非选择性阿片受体拮抗剂纳洛酮分别给予小鼠和大鼠实验组。
我们观察到,在醋酸扭体试验中,选择性育亨宾(1mg/kg,腹腔注射;AEBM处理组和育亨宾预处理AEBM组分别有14.50±2.26次和37.17±2.14次扭体)和选择性β1阿替洛尔受体阻滞剂(1mg/kg,腹腔注射;AEBM处理组和育亨宾预处理AEBM组分别有14.50±2.26次和31.00±5.44次扭体)预处理可阻止AEBM的抗伤害感受作用。在福尔马林试验中,发现5-羟色胺受体拮抗剂赛庚啶(1mg/kg,腹腔注射;AEBM处理组和赛庚啶预处理AEBM组在第一阶段即0-5分钟分别为47.33±2.25秒和113.50±3.83秒,在第二阶段即20-30分钟分别为26.67±3.83秒和88.17±7.27秒)预处理可逆转AEBM导致的舔舐时间缩短。非选择性阿片受体拮抗剂纳洛酮(2mg/kg,腹腔注射;AEBM处理组和纳洛酮处理组分别为282.35和107.35)预处理可阻止AEBM导致的甩尾潜伏期百分比增加。
我们的结果表明内源肾上腺素能、5-羟色胺能和阿片样物质系统参与了假马齿苋水提取物的镇痛作用机制。